Batoclimab Fails Phase 3 TED Studies; Roivant Expands Brepocitinib Program & Repurchases $109.7M Shares
ROIV has more than doubled off its 52-week low of $8.73.
Summary
Roivant Sciences reported mixed clinical updates, with a Phase 3 failure for batoclimab in thyroid eye disease, alongside the initiation of a new Phase 2b/3 program for brepocitinib and a significant share repurchase.
Key Events · Product Development and Regulatory · ROIV
-
Batoclimab Fails Phase 3 TED Studies
Immunovant's batoclimab failed to meet its primary endpoint in two Phase 3 clinical studies evaluating it as a treatment for active, moderate-to-severe thyroid eye disease (TED). This is a significant clinical setback for a late-stage asset.
-
New Brepocitinib Program Initiated
Roivant announced a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder with no FDA-approved therapies. This marks the fourth indication for brepocitinib in late-stage development.
-
Significant Share Repurchase
For the three months ended March 31, 2026, the company repurchased 3,956,362 common shares for an aggregate purchase price of approximately $109.7 million.
Analysis · ROIV · Life Sciences
This filing presents a mixed bag of significant news for Roivant Sciences. The primary negative is the failure of Immunovant's batoclimab to meet its primary endpoint in two Phase 3 studies for thyroid eye disease (TED). This is a major clinical setback for a late-stage asset and will likely weigh heavily on investor sentiment. However, the company also announced a substantial share repurchase of $109.7 million, which represents a notable commitment to returning capital to shareholders and signals management's confidence in the company's valuation. Additionally, Roivant expanded its brepocitinib development program into a new Phase 2b/3 trial for lichen planopilaris (LPP), an indication with high unmet medical need, which could be a future growth driver. Investors will need to balance the immediate negative impact of the clinical failure against these positive financial and pipeline developments.
At the time of this filing, ROIV was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9B. The 52-week trading range was $8.73 to $30.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.